Financial Data and Key Metrics Changes - For the full year 2025, the company achieved approximately 15% year-over-year revenue growth and a 21% increase in new account generation [4] - Total revenue for the fourth quarter of 2025 was $3.9 million, reflecting a 13% growth compared to the fourth quarter of 2024 [16] - Gross profit for the fourth quarter was $2 million, an increase of $200,000 or 13% compared to the same period last year, with a gross margin of 50% [16] Business Line Data and Key Metrics Changes - The CapsoCam Plus small-bowel capsule endoscopy solution saw approximately 9,400 patients imaged in the fourth quarter, up from approximately 8,374 in the prior year period, representing year-over-year growth of 12% [12] - New account growth for CapsoCam Plus increased by 16% year-over-year in the fourth quarter [14] - The number of hospital system customers increased by 87% in the fourth quarter compared to the same period last year [15] Market Data and Key Metrics Changes - The company reported that more than 161,000 patients have been imaged with CapsoCam Plus as of December 31, 2025 [4] - The company is expanding its international presence, including a dedicated team in Germany and partnerships with distributors in high-potential markets [13] Company Strategy and Development Direction - The long-term vision is to deliver an ingestible capsule capable of screening for multiple cancers in a single non-invasive procedure [4] - The company is focusing on advancing its AI-enabled roadmap and has submitted a 510(k) application for an AI-assisted reading module [6] - The development strategy for CapsoCam Colon has been refined to prioritize a second-generation capsule, with a submission expected in the third quarter of 2026 [8] Management's Comments on Operating Environment and Future Outlook - Management believes the company is well-positioned heading into 2026 with a growing commercial base and a differentiated AI-enabled platform [11] - The company is entering a highly competitive phase of execution, with continued commercial momentum and a disciplined pipeline strategy [18] - Management expressed confidence in the strategy and the ability to invest in product innovation and clinical development [10] Other Important Information - The company completed a $14 million private placement to strengthen its balance sheet, reflecting continued investor confidence [10][17] - The company is pioneering a novel visual assessment method for pancreatic cancer detection, with a clinical study expected to begin in the second quarter of 2026 [9] Q&A Session Summary Question: Feedback on Gen 2 CapsoCam Colon efforts - Management reported that enrollment is going well, with no delays anticipated for the FDA submission by the end of Q3 [22][23] Question: Criteria for breakthrough designation application for pancreatic cancer detection - Management explained that a scoring system is being developed to establish diagnostic criteria, which will be important for FDA application [24][25][26] Question: CapsoCam development timeline and patient recruitment - Management indicated that over 500 patients have been enrolled across 11 sites, with a target of 800 for Gen 2 [34][35] Question: Anticipated review time for 510(k) submission - Management expects the FDA to take about six months for clearance, aiming for commercial availability in Q1 2027 [37]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $3.5 million, reflecting a 19% increase compared to Q3 2024, driven by an increase in the number of CapsoCam Plus capsules sold [15] - Gross margin was 54% for the quarter, consistent with expectations as the company scales [15] - Net loss for Q3 2025 was $7.9 million, compared to a net loss of $5.8 million in Q3 2024 [16] - Cash and equivalents at the end of the quarter were $17.8 million, an increase from $1.1 million at June 30, 2025, following the completion of the IPO [16] Business Line Data and Key Metrics Changes - CapsoCam Plus has been used by over 151,000 patients, with approximately 8,336 patients using the system in Q3 2025, representing a 20% year-over-year growth [11] - New account generation grew by 31% in Q3 2025 compared to the same quarter in 2024, indicating strong physician adoption [14] - A 24% increase in GI clinics and mega GI groups was noted in Q3 2025 over the same quarter last year [14] Market Data and Key Metrics Changes - The company is gaining traction in hospitals and GPOs, with a 26% increase in hospital system customers over the prior year [14] - The U.S. direct sales team included 26 representatives, supported by seven regional sales managers and trainers as of September 30, 2025 [12] Company Strategy and Development Direction - The long-term vision is to deliver an ingestible capsule that can screen for multiple cancers in a single non-invasive procedure powered by advanced imaging and AI [4] - The company is investing in AI to improve existing products and plans to submit an application to the FDA by year-end 2025 for AI technology incorporation into CapsoCam Plus [5][6] - CapsoVision is pursuing Breakthrough Device Designation for its non-invasive capsule endoscopy system to enable earlier detection of pancreatic ductal adenocarcinoma [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum across the business, highlighting commercial growth, pipeline expansion, and advancements in AI-assisted diagnostics [18] - The application for Breakthrough Device Designation reflects the urgent need for early detection of pancreatic cancer and the promise of the company's technology [18] - The company is strengthening its leadership team and executing a clear growth plan following a successful IPO [19] Other Important Information - The company has a development agreement with Canon Incorporated to design next-generation CMOS imaging sensors, marking a key step in advancing its innovation pipeline [16] - R&D expenses related to the Canon agreement were $1.6 million for Q3 2025, considered a one-time charge [15] Q&A Session Summary Question: Impact of AI feature submission on other milestones - Management indicated that the FDA review typically takes three to six months, so the approval should be available in the second half of the year [22] Question: Operating expenses related to Canon agreement - The $1.6 million expense for R&D for Canon is a one-time charge, and future core R&D expenses should be lower [23] Question: Clinical data for breakthrough designation application - A small feasibility study conducted six years ago showed promising results, with two out of 20 subjects diagnosed with cancer [28] Question: Timeline for Canon CMOS sensor - The pivotal study for pancreatic cancer will proceed without waiting for the Canon sensor, which is expected to be ready in 2026 [35] Question: Commercial organization headcount - The current sales team will be maintained, with plans to add two additional territories in 2026 as needed [36]